

**CONNATE MYXEDEMA- AN INADEQUATE THYROID HORMONE  
PRODUCTION IN NEWBORN INFANTS**

**ABSTRACT:**

Connate myxedema is also known as congenital hypothyroidism is an inborn endocrine disorder, influence 1 in every 3000 to 4000 infants. Numerous genetic defects are compatriot with perpetual congenital hypothyroidism. Ambient atmosphere, iatrogenic and immunologic factors are known to persuade transient congenital hypothyroidism, which rectifies within first few months of life. Molecular defects of thyroid oxidase system which is serened of at least two proteins may be intricated in pathogenesis of lasting transient congenital hypothyroidism in infants with faults in iodide organification, for which the oxidase system is needed. Congenital hypothyroidism is predominantly sporadic but up to 2% of thyroid dysgenesis is inherited and congenital hypothyroidism due to organification faults is often recessively inherited. Levothyroxine is the drug of choice. An infant of 10 months old was presented with hoarseness while crying and noisy breathing. I had reported a case in which patient was diagnosed with congenital hypothyroidism and is being treated with levothyroxine.

**KEYWORDS:** Congenital hypothyroidism, dysgenesis, dyshormogenesis, Thyro Oxidase 2.

22 **BACKGROUND:**

23 Congenital hypothyroidism is an innate endocrine disorder, **influence** 1 in every 3000 to 4000  
24 newborns. Numerous genetic defects are kindred with permanent congenital hypothyroidism.  
25 Environmental, induced and immunologic factors are known to prompt transient congenital  
26 hypothyroidism, which settles within first few months of life. Molecular defects of thyroid  
27 oxidase system which is **tranquiled** of at least two proteins may be incriminated in pathogenesis  
28 of persistent transient congenital hypothyroidism in new borns with defects in iodide  
29 organification, for which the oxidase system is essential. Biallelic deactivating mutations in the  
30 thyro oxidase 2 gene results in upset of thyroid hormone synthesis and related with severe and  
31 **everlasting** congenital hypothyroidism. Monoallelic mutations are correlated with milder,  
32 transient hypothyroidism caused by inadequate thyroidal **fabrication** of hydrogen peroxide. It  
33 averts the synthesis of adequate quantities of thyroid hormones to encounter the large demand for  
34 thyroid hormones at the inception of life.<sup>1</sup> In spite of the fact that the current experimental  
35 writing on the neurocognitive impacts of clinical hypothyroidism is very simple, clearly every  
36 individual analyzed as having this issue ought to be **alluded** for exhaustive neuropsychological  
37 assessment in perspective on the **solid hazard** for intellectual dreariness.<sup>2</sup> Beginning dose of 50  
38 µg/day (12-17 µg/kg every day) for raised serum T4 and free T4 focuses to target run by 3 days  
39 and standardized TSH by about fourteen days of treatment. **We prescribe thought of a to some**  
40 **degree higher???** "target run" of 10 to 18 µg/dL for T4 and 2 to 5.0 ng/dL for free T4 during the  
41 initial 2 weeks of L-thyroxine treatment. **Following 2 weeks of treatment, the objective range**  
42 **drops to 10 to 16 µg/dL for T4 and 1.6 to 2.2 for free T4.**<sup>3</sup>

43

44 **CASE PRESENTATION:**

45 An infant of 10 months old was admitted to hospital with chief complaints of hoarseness while  
46 crying since 3months which is increasing day by day, noisy breathing since 2 months and not  
47 gaining weight. Patient had a coarse facial feature as shown in **figure.1** underneath. The weight  
48 of child at the time of birth was 3.2 kgs. The patient mother is a known case of hypothyroidism  
49 since 2 years and was on medication (THYROXINE). Thyroid profile of patient is as follows:  
50 Triiodothyronine: 0.34 ng/ml (Normal range: 1.0-2.60 ng/ml), Total thyroxine: 0.6 mcg/100ml  
51 (Normal range: 6-14 mcg/100ml), Thyroid Stimulating Hormone: >100 µU/ml (Normal range:  
52 0.7-6.4 µU/ml). Complete blood picture report is as following: Hemoglobin: 8.4 Gms%, RBC:  
53 3.2 M/cmm, Haematocrit (P.C.V): 25 vol%, Reticulocyte count: 0.1%. Thyroid profile of patient  
54 revealed the increased levels of thyroid stimulating hormone and decreased levels of thyroxine  
55 and triiodothyronine. Impression of complete blood picture is Normocytic Hypochromic  
56 Anemia. Patient was diagnosed with cretinism. Currently the patient is being treated with  
57 LEVOTHYROXINE 50 mcg/day.

58 **CONSENT:**

59 Written informed consent was obtained from the patient care taker for the publication of this case  
60 report and escorting images.

61



62

63

Figure.1: Coarse facial feature in patient.

64 **DISCUSSION:**

65 Congenital hypothyroidism is an ordinary neonatal metabolic disorder and consequences in  
66 neurodevelopment disability and infertility if untreated. Congenital hypothyroidism is occasional  
67 but up to 2% of thyroid dysgenesis is inherited and congenital hypothyroidism due to  
68 organification **faults** is often recessively hereditary. The candidate genes interconnected with this  
69 genetic disorder form 2 main groups: one generating thyroid gland dysgenesis and other  
70 generating dyshormogenesis. Genes correlated with thyroid gland dysgenesis encompass those  
71 engendering non-syndromic congenital hypothyroidism (TSH receptor) and those generating  
72 syndromic congenital hypothyroidism (TTF-1, TTF-2, PAX-8 and G5 $\alpha$ ). Genes associated with  
73 dyshormogenesis comprise sodium iodide symporter, thyroid peroxidase, pendrin, thyroglobulin  
74 and most latterly, thyro oxidase 2. Modern evidence proposes that third group of congenital  
75 hypothyroidism conditions are interconnected with defects in iodothyronine transporter, MCT8,  
76 where hypothyroidism is associated with neurologic shortfall.<sup>4</sup> Autosomal dominant transmission

77 of mutations of NKX2-1 may lead to congenital hypothyroidism, neonatal respiratory **anguish** at  
78 term and persistent neurologic manifestations such as dysarthria, choreoathetosis and ataxia in  
79 families with pretentious subjects in several generations.<sup>5</sup> The clinical manifestations are tenuous  
80 or not present at birth. This is due to trans-placental transit of few maternal thyroid hormones,  
81 while many new borns have some thyroid production of their own. Symptoms involve hoarse  
82 cry, neonatal hyperbilirubinemia, constipation for more than 3 weeks and lethargy. The most  
83 familiar signs are cold or mottled skin, umbilical hernia and macroglossia. Persistent jaundice  
84 and poor feeding are most noticeable clinical features. The diagnosis must be established by  
85 finding an increased serum thyroid stimulating hormone and thyroxine or free thyroxine level.  
86 Serum thyroid stimulating hormone and free thyroxine should be **resolved**? for every 1-2  
87 months in the first 6months of life and for every 3-4 months subsequently. Levothyroxine is the  
88 drug of choice; the endorsed starting dose is 10-15 mcg/kg/day. The immediate goals of treatment  
89 are to quickly raise the serum thyroxine above 130nmol/l (10mcg/dl) and homogenize the serum  
90 thyroid stimulating hormone levels.<sup>6</sup> In some cases which were reported, the patients were  
91 acknowledged with clinical symptoms of lethargy, hoarse voice, failure to gain weight, feeding  
92 difficulties, dry skin, prominent tongue, difficulty in breathing and umbilical hernia.<sup>7,8</sup> In this  
93 case the patient had a history of hoarseness while crying, noisy breathing and not gaining weight  
94 as seen in the earlier cases which were reported.

#### 95 **CONCLUSION:**

96 Levothyroxine is the drug of choice; the recommended starting dose is 10-15 mcg/kg/day. Here  
97 in this case the patient is being treated with LEVOTHYROXINE 50 mcg/day which is  
98 appropriate to the patient's condition.

99 **CONFLICTS OF INTEREST:**

100 The authors declare that there's no conflict of interest concerning the publication of paper.

101 **REFERENCE:**

- 102 1. Jose C, Hennie B, Marlies JE, Paul AS, Frank B, Jan JM, Thomas V, Ris Stalpers C.  
103 Inactivating Mutations in the Gene for Thyroid Oxidase 2 (*THOX2*) and Congenital  
104 Hypothyroidism. *New England Journal of Medicine*. 2002; 347 (2): 95-102.
- 105 2. Anthony T. Neurocognitive Aspects of Hypothyroidism. *Arch Intern Med*. 1988; 158(13):  
106 1413-18.
- 107 3. Karin A, Scott H, Leanne Rein RN, David S, Richard M, Michael S, Jerald C, Stephen H.  
108 Initial treatment dose of L-thyroxine in congenital hypothyroidism. *The Journal of Pediatrics*.  
109 2002; 141(6): 786-92.
- 110 4. Park SM, Chatterjee VKK. Genetics of congenital hypothyroidism. *Journal of medical*  
111 *genetics*. 2005; 42(5): 379-89.
- 112 5. Daniel A, Iris G, Becky T, Mena S. Autosomal dominant transmission of congenital  
113 hypothyroidism, neonatal respiratory distress, and ataxia caused by a mutation of *NKX2-1*.  
114 *The journal of pediatrics*. 2004; 145(2): 190-93.
- 115 6. Maynika V, Stephen H. Congenital hypothyroidism. *Orphanet journal of rare diseases*. 2010;  
116 5(1): 17.
- 117 7. Samir N. Respiratory Manifestations in Infants with Hypothyroidism. *Archives of Disease in*  
118 *childhood*. 1962; 37(196): 603-05.
- 119 8. Frances B. Hypothyroidism in Childhood. *British Medical Journal*. 1951; 1(4716): 1169-76.